A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

Summary

The objective of this study is to investigate the efficacy and safety of three different doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period of 6 weeks in pediatric patients (aged 13-17 years) with schizophrenia

Timeline

Start

2010-08

Primary completion

2014-11

Completion

2014-11

Drugs

Indications